Pfizer, Hospira Beat FCA Suit Over Faulty Infusion Pumps

Law360 (March 15, 2019, 5:34 PM EDT) -- Pfizer Inc. and its Hospira Inc. unit have beat a False Claims Act suit accusing them of silently fixing defects with infusion pumps without telling customers or the U.S. Food and Drug Administration, with an Illinois federal judge saying the whistleblower didn't specifically allege any Medicare fraud.

U.S. District Judge John Robert Blakey on Thursday granted the companies' motion to dismiss because relator Michael Thornton didn't allege that any false claims were submitted to Medicare or Medicaid as a result of Hospira's alleged misconduct. Then, since there was no FCA-protected activity at play, the judge said Hospira didn't retaliate against Thornton...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!